AU2017232496B2 - Compositions and methods for the treatment of a beta-catenin-associated disease or disorder - Google Patents

Compositions and methods for the treatment of a beta-catenin-associated disease or disorder Download PDF

Info

Publication number
AU2017232496B2
AU2017232496B2 AU2017232496A AU2017232496A AU2017232496B2 AU 2017232496 B2 AU2017232496 B2 AU 2017232496B2 AU 2017232496 A AU2017232496 A AU 2017232496A AU 2017232496 A AU2017232496 A AU 2017232496A AU 2017232496 B2 AU2017232496 B2 AU 2017232496B2
Authority
AU
Australia
Prior art keywords
catenin
nucleic acid
subject
inhibitor molecule
acid inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017232496A
Other languages
English (en)
Other versions
AU2017232496A1 (en
Inventor
Marc Abrams
Shanthi Ganesh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dicerna Pharmaceuticals Inc
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of AU2017232496A1 publication Critical patent/AU2017232496A1/en
Application granted granted Critical
Publication of AU2017232496B2 publication Critical patent/AU2017232496B2/en
Priority to AU2023200960A priority Critical patent/AU2023200960A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017232496A 2016-03-16 2017-03-15 Compositions and methods for the treatment of a beta-catenin-associated disease or disorder Ceased AU2017232496B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023200960A AU2023200960A1 (en) 2016-03-16 2023-02-17 Compositions and Methods for the Treatment of a Beta-Catenin-Associated Disease or Disorder

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662309449P 2016-03-16 2016-03-16
US62/309,449 2016-03-16
US201662318529P 2016-04-05 2016-04-05
US62/318,529 2016-04-05
US201662365164P 2016-07-21 2016-07-21
US62/365,164 2016-07-21
PCT/US2017/022510 WO2017160983A1 (en) 2016-03-16 2017-03-15 Compositions and methods for the treatment of a beta-catenin-associated disease or disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023200960A Division AU2023200960A1 (en) 2016-03-16 2023-02-17 Compositions and Methods for the Treatment of a Beta-Catenin-Associated Disease or Disorder

Publications (2)

Publication Number Publication Date
AU2017232496A1 AU2017232496A1 (en) 2018-10-04
AU2017232496B2 true AU2017232496B2 (en) 2022-11-24

Family

ID=59850959

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017232496A Ceased AU2017232496B2 (en) 2016-03-16 2017-03-15 Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
AU2023200960A Abandoned AU2023200960A1 (en) 2016-03-16 2023-02-17 Compositions and Methods for the Treatment of a Beta-Catenin-Associated Disease or Disorder

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023200960A Abandoned AU2023200960A1 (en) 2016-03-16 2023-02-17 Compositions and Methods for the Treatment of a Beta-Catenin-Associated Disease or Disorder

Country Status (6)

Country Link
US (3) US10821112B2 (enExample)
EP (1) EP3429598A4 (enExample)
JP (2) JP6987084B2 (enExample)
AU (2) AU2017232496B2 (enExample)
CA (1) CA3017963A1 (enExample)
WO (1) WO2017160983A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017232496B2 (en) * 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
JP2021500026A (ja) * 2017-10-18 2021-01-07 ディセルナ ファーマシューティカルズ インコーポレイテッド βカテニン核酸阻害剤分子
AU2019205904A1 (en) 2018-01-05 2020-06-18 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
JP7535047B2 (ja) * 2018-12-12 2024-08-15 ディセルナ ファーマシューティカルズ インコーポレイテッド トリループを含む二本鎖核酸インヒビター分子
WO2020226960A1 (en) * 2019-05-03 2020-11-12 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
WO2023122316A2 (en) * 2021-12-23 2023-06-29 Aligos Therapeutics, Inc. SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF
US20250152677A1 (en) * 2022-02-14 2025-05-15 Institut National de la Santé et de la Recherche Médicale Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstreatm of meg3 in the dlk1/dio3 locus
CN119923258A (zh) * 2022-10-21 2025-05-02 递归医药公司 在wnt通路肿瘤阻抑基因中具有突变的癌症的治疗
WO2025147555A1 (en) * 2024-01-05 2025-07-10 Recursion Pharmaceuticals, Inc. Rec-4881 (tak-733) for use in treating or preventing colorectal cancer and related diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018754A2 (en) * 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2013066944A2 (en) * 2011-10-31 2013-05-10 The Board Of Regents Of The University Of Texas System Biomarkers for cancer characterization and treatment
WO2013105022A2 (en) * 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
WO2015051252A1 (en) * 2013-10-03 2015-04-09 Duke University Compositions and methods for treating cancer with jak2 activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535388A (ja) * 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US20100055782A1 (en) 2007-03-02 2010-03-04 Mdrna, Inc. Nucleic acid compounds for inhibiting myc gene expression and uses thereof
DK2591105T3 (en) 2010-07-06 2017-07-31 Dicerna Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR SPECIFIC INHIBITION OF BETA-CATENIN USING DOUBLE-STRENGTH RNA
JP2015529467A (ja) 2012-09-14 2015-10-08 ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 二本鎖ｒｎａによるｍｙｃの特異的阻害に関する方法および組成物
US10201556B2 (en) * 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
CN105163584B (zh) 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
TWI839690B (zh) * 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
KR102186363B1 (ko) 2013-09-06 2020-12-04 삼성전자주식회사 c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
KR102192591B1 (ko) 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
US9895312B2 (en) 2014-04-08 2018-02-20 Pablo E. Vivas-Mejia Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
AU2017232496B2 (en) * 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018754A2 (en) * 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2013066944A2 (en) * 2011-10-31 2013-05-10 The Board Of Regents Of The University Of Texas System Biomarkers for cancer characterization and treatment
WO2013105022A2 (en) * 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
WO2015051252A1 (en) * 2013-10-03 2015-04-09 Duke University Compositions and methods for treating cancer with jak2 activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUAN J. et al., "Diminished WNT- Beta-catenin-c-MYC signaling is a barrier for malignant progression of BRAF V600E-induced lung tumors", Genes and Development, (2014), vol. 28, pages 561 - 575 *

Also Published As

Publication number Publication date
US11504374B2 (en) 2022-11-22
CA3017963A1 (en) 2017-09-21
AU2023200960A1 (en) 2023-04-27
US20210015820A1 (en) 2021-01-21
JP2022033848A (ja) 2022-03-02
EP3429598A1 (en) 2019-01-23
EP3429598A4 (en) 2020-04-01
US20190070180A1 (en) 2019-03-07
AU2017232496A1 (en) 2018-10-04
US20230190753A1 (en) 2023-06-22
US10821112B2 (en) 2020-11-03
WO2017160983A1 (en) 2017-09-21
JP7321236B2 (ja) 2023-08-04
JP2019512543A (ja) 2019-05-16
JP6987084B2 (ja) 2021-12-22

Similar Documents

Publication Publication Date Title
US11504374B2 (en) Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
EP3240796B1 (en) Rna interference compositions and methods for malignant tumors
JP7392954B2 (ja) トリプルネガティブ乳癌の治療方法
US20220154189A1 (en) Compositions and methods for the treatment of kras associated diseases or disorders
EP3284481B1 (en) Cell death inducing agent for cells having braf gene mutation, agent for inhibiting proliferation of said cells and pharmaceutical composition for treating patient suffering from effects of abnormal proliferation of said cells
CN1703229B (zh) 治疗前列腺和其他癌的组合物和其制备药物的用途
WO2021184990A1 (zh) 一种增敏剂药物及药物组合及应用
US11090266B2 (en) Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
CN105407974A (zh) 抗癌组合
Cina et al. A novel lipid nanoparticle nbf-006 encapsulating glutathione s-transferase p siRNA for the treatment of KRAS-driven non–small cell lung cancer
KR20200052294A (ko) Setd2의 저해에 의한 암의 치료 방법
JP5406024B2 (ja) Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法
TW201728334A (zh) 用於治療癌症之組合物及方法
WO2017160797A1 (en) Combination therapy with c-myc nucleic acid inhibitors and selective cdk7 inhibitors
JP2026504743A (ja) 膵管腺癌に対するｅｇｆｒ、ｒａｆ１、およびｓｔａｔ３を阻害する三剤併用療法
JP2012219085A (ja) 頭頸部癌及び食道癌用抗癌剤及び増強剤
WO2019107487A1 (ja) マイクロｒｎａ及びその誘導体を有効成分とする医薬組成物
US8927598B2 (en) Treating oncogenic Ras driven cancers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired